Resultados da pesquisa - Lataillade, Max

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Data... Por Gartland, Margaret, Arnoult, Eric, Foley, Brian T, Lataillade, Max, Ackerman, Peter, Llamoso, Cyril, Krystal, Mark

Obter o texto integral Obter o texto integral Obter o texto integral

Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry... Por Li, Zhufang, Zhou, Nannan, Sun, Yongnian, Ray, Neelanjana, Lataillade, Max, Hanna, George J., Krystal, Mark

Obter o texto integral Obter o texto integral Obter o texto integral

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants Por Johnson, Mark, Pene Dumitrescu, Teodora, Joshi, Samit R., Mathew, Ashwin, Bainbridge, Veronica, Zhan, Joyce, Lataillade, Max

Obter o texto integral Obter o texto integral Obter o texto integral

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir Por Lataillade, Max, Zhou, Nannan, Joshi, Samit R., Lee, Sangil, Stock, David A., Hanna, George J., Krystal, Mark

Obter o texto integral Obter o texto integral Obter o texto integral

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay Por Gartland, Margaret, Zhou, Nannan, Stewart, Eugene, Pierce, Amy, Clark, Andrew, Ackerman, Peter, Llamoso, Cyril, Lataillade, Max, Krystal, Mark

Obter o texto integral Obter o texto integral Obter o texto integral

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc Por Rose, Ronald, Gartland, Margaret, Li, Zhufang, Zhou, Nannan, Cockett, Mark, Beloor, Jagadish, Lataillade, Max, Ackerman, Peter, Krystal, Mark

Obter o texto integral Obter o texto integral Obter o texto integral

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study Por Dicker, Ira, Zhang, Sharon, Ray, Neelanjana, Beno, Brett R., Regueiro-Ren, Alicia, Joshi, Samit, Cockett, Mark, Krystal, Mark, Lataillade, Max

Obter o texto integral Obter o texto integral Obter o texto integral

Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing Por Lataillade, Max, Chiarella, Jennifer, Yang, Rong, DeGrosky, Michelle, Uy, Jonathan, Seekins, Daniel, Simen, Birgitte, St. John, Elizabeth, Moreno, Elizabeth, Kozal, Michael

Obter o texto integral Obter o texto integral Obter o texto integral

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates Por Ray, Neelanjana, Li, Tianbo, Lin, Zeyu, Protack, Tricia, van Ham, Petronella Maria, Hwang, Carey, Krystal, Mark, Nijhuis, Monique, Lataillade, Max, Dicker, Ira

Obter o texto integral Obter o texto integral Obter o texto integral

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects Por Gupta, Shaili, Lataillade, Max, Kyriakides, Tassos C., Chiarella, Jennifer, St. John, Elizabeth P., Webb, Suzin, Moreno, Elizabeth A., Simen, Birgitte B., Kozal, Michael J.

Obter o texto integral Obter o texto integral Obter o texto integral

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis Por Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max

Obter o texto integral Obter o texto integral Obter o texto integral

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis Por Brinson, Cynthia, Lalezari, Jacob, Latiff, Gulam H, Thompson, Melanie, Echevarría, Juan, Treviño-Pérez, Sandra, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Obter o texto integral Obter o texto integral

Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis Por Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Obter o texto integral Obter o texto integral Obter o texto integral

1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis Por Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

Obter o texto integral Obter o texto integral

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants Por Pene Dumitrescu, Teodora, Joshi, Samit R., Xu, Jianfeng, Zhan, Joyce, Johnson, Mark, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Davidson, Antonia M., Lataillade, Max, Min, Sherene

Obter o texto integral Obter o texto integral Obter o texto integral

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults Por Pene Dumitrescu, Teodora, Joshi, Samit R., Xu, Jianfeng, Greene, Thomas J., Johnson, Mark, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Pham, Theresa T., Lataillade, Max, Min, Sherene

Obter o texto integral Obter o texto integral Obter o texto integral

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals Por Anderson, Sarah-Jane, Murray, Miranda, Cella, David, Grossberg, Robert, Hagins, Debbie, Towner, William, Wang, Marcia, Clark, Andrew, Pierce, Amy, Llamoso, Cyril, Ackerman, Peter, Lataillade, Max

Obter o texto integral Obter o texto integral Obter o texto integral

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study Por Lataillade, Max, Chiarella, Jennifer, Yang, Rong, Schnittman, Steven, Wirtz, Victoria, Uy, Jonathan, Seekins, Daniel, Krystal, Mark, Mancini, Marco, McGrath, Donnie, Simen, Birgitte, Egholm, Michael, Kozal, Michael

Obter o texto integral Obter o texto integral Obter o texto integral

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety,... Por Landry, Ishani, Zhu, Li, Abu Tarif, Malaz, Hruska, Matthew, Sadler, Brian M., Pitsiu, Maria, Joshi, Samit, Hanna, George J., Lataillade, Max, Boulton, David W., Bertz, Richard J.

Obter o texto integral Obter o texto integral Obter o texto integral

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women Por Pene Dumitrescu, Teodora, Greene, Thomas J., Joshi, Samit R., Xu, Jianfeng, Johnson, Mark, Halliday, Fiona, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Pham, Theresa T., Lataillade, Max, Min, Sherene

Obter o texto integral Obter o texto integral Obter o texto integral